Risks of testosterone replacement therapy in ageing men
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Testosterone has been available to practitioners for several decades. However, testosterone prescriptions have increased in recent years partly because of the introduction of newer delivery systems that are topical and have good bioavailability. In the US alone, approximately 2 million prescriptions for testosterone were written in 2002. This represents a 30% increase from 2001 and a 170% increase from 1999. There has also been a 500% increase in prescription sales in the past 10 years. The rise in prescriptions may be in part due to the increasing recognition of hypogonadism in ageing males or andropause. Treatment relating to hypogonadism has relieved symptoms and improved the quality of life of many individuals. Epidemiological studies point toward an association with increased morbidity and mortality, with low testosterone states in ageing males. For example, there is a higher prevalence of depression, coronary heart disease, osteoporosis, fracture rates, frailty and even dementia with low testosterone states. Recently, there have been some concerns raised regarding the long-term safety of testosterone replacement therapy (TRT) from the Institute of Medicine. Current evidence suggests no causal relationship between prostate cancer and physiological dosing of testosterone, especially with careful selection and monitoring of patients. Cardiovascular risks have, overall, been neutral, although suggestions have been made that there are positive vasodilatory properties with testosterone. Mild eythrocytosis can be a common side effect of TRT, but thromboembolic events have rarely been reported in the literature. This paper addresses the evidence to date regarding the safety aspects of TRT. The medical-legal implications of TRT for men at this point in time is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease
Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., & Collins, P. (1999) · Circulation · doi:10.1161/01.cir.100.16.1690 · Cited by 451 · cited 2×
“On the other hand, several investigators have shown positive dilatory effects on coronary vessels with testosterone in intervention trials [4,5].”
BackgroundDobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381 · cited 2×
“In the study from John Hopkins University, a 24-week trial that randomised 66 adult hypogonadal men (22 – 65 years of age) found no differences in lipids between the treatment group and the placebo group [14].”
BackgroundBehre, H. M., Bohmeyer, J., & Nieschlag, E. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03929.x · Cited by 335
The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men
Liu, P. Y., Yee, B., Wishart, S. M., Jimenez, M., Jung, D. G., Grunstein, R. R., & Handelsman, D. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030236 · Cited by 275
Fogel, R. B., Malhotra, A., Pillar, G., Pittman, S. D., Dunaif, A., & White, D. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7316 · Cited by 274
Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis
Whitsel, E. A., Boyko, E. J., Matsumoto, A. M., Anawalt, B. D., & Siscovick, D. S. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00833-6 · Cited by 240 · cited 1×
“performed a meta-analysis of the effects of intramuscular testosterone on lipids [13].”
MethodRHODEN, E. L., & MORGENTALER, A. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091104.71869.8e · Cited by 186 · cited 1×
“demonstrated that testosterone enanthate replacement in men with prostatic intraepithelial neoplasia (PIN) did not have a statistically significant increase of prostate cancer after 12 months of intramuscular injection or transdermal gel therapy [25].”
BackgroundEffect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
Zgliczynski, S., Ossowski, M., Slowinska-Srzednicka, J., Brzezinska, A., Zgliczynski, W., Soszynski, P., Chotkowska, E., Srzednicki, M., & Sadowski, Z. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05673-4 · Cited by 167
Effect of testosterone administration on upper airway collapsibility during sleep
Cistulli, P. A., Grunstein, R. R., & Sullivan, C. E. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.2.8306057 · Cited by 120
Kouri, E. M., Pope, H. G., & Oliva, P. S. (1996) · Clinical Journal of Sport Medicine · doi:10.1097/00042752-199607000-00003 · Cited by 31 · cited 1×
“However, studies in older individuals with topical versions of testosterone have not been proven to be adverse [10-12].”
Background
Cited by
Burden of Dizziness and Vertigo in the Community
Neuhauser, H. K., Radtke, A., von Brevern, M., Lezius, F., Feldmann, M., & Lempert, T. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2118 · Cited by 538
Endocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221
Androgen Treatment and Muscle Strength in Elderly Men: A Meta‐Analysis
Ottenbacher, K. J., Ottenbacher, M. E., Ottenbacher, A. J., Acha, A. A., & Ostir, G. V. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00938.x · Cited by 173
Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample
Hall, S. A., Esche, G. R., Araujo, A. B., Travison, T. G., Clark, R. V., Williams, R. E., & McKinlay, J. B. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0021 · Cited by 167
“Available data suggest sales of prescription testosterone are on the rise (35), despite debate over the appropriateness of its use (36, 37) and the absence of changes in approved indications for testosterone treatment (38).”
BackgroundTreatment of hypogonadism: Current and future therapies
Thirumalai, A., Berkseth, K. E., & Amory, J. K. (2017) · F1000Research · doi:10.12688/f1000research.10102.1 · Cited by 36
Metadata
- Authors
- Tan, R., & Salazar, J.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2004-11
- Volume
- 3
- Issue
- 6
- Pages
- 599-606
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2148738135
- Cited by
- 41
- References
- 12
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.